MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from warrant inducement...
Proceeds from sale of common sto...
Equity-based compensation
Others
Negative Cash Flow Breakdown
Net loss
Issuance costs from warrant indu...
Issuance costs for sale of commo...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-3,322,565
-2,496,540
-3,038,990
-2,685,705
Depreciation expense
504
555
555
401
Equity-based compensation
672,102
252,364
325,103
473,384
Interest receivable
-161
370
-7,695
-6,248
Prepaid expenses
-17,966
227,931
84,125
-242,342
Deferred offering costs
-17,933
7,265
15,504
66,977
Other assets
-
-
-1
0
Accounts payable
47,104
174,146
36,536
-281,482
Accrued liabilities
333,641
-697,176
198,770
-45,361
Net cash used in operating activities
-2,233,154
-3,002,217
-2,569,959
-2,357,150
Investment in property and equipment
-
-
0
1,853
Disposal of property & equipment
1,441
-
-
-
Proceeds from the sale of common stock and warrants
-
-
-2,250,008
-
Net cash provided by (used in) investing activities
1,441
-
0
-1,853
Issuance costs for the sale of common stock and warrants
-
-
291,883
-
Proceeds from warrant inducements
2,570,274
-
-
-
Proceeds from sale of common stock under atm
-
1,366,535
0
16,003
Issuance costs from warrant inducement
338,667
-
-
-
Proceeds from sale of common stock under atm
1,522,058
-63,970
846,108
667,980
Issuance costs for sale of common stock under atm
75,419
-
86,567
35,628
Net cash provided by financing activities
2,311,711
1,302,565
2,717,666
648,355
Net change in cash and cash equivalents
79,998
-1,699,652
147,707
-1,710,648
Cash and cash equivalents beginning of the period
2,308,137
4,007,789
3,860,082
10,017,942
Cash and cash equivalents end of the period
2,388,135
2,308,137
4,007,789
3,860,082
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from warrant
inducements
$2,570,274
Disposal of property &
equipment
$1,441
Proceeds from sale of
common stock under atm
$1,522,058
(-54.53%↓ Y/Y)
Net cash provided by
financing activities
$2,311,711
(-28.44%↓ Y/Y)
Net cash provided by
(used in) investing...
$1,441
(144.32%↑ Y/Y)
Canceled cashflow
$1,780,621
Net change in cash
and cash...
$79,998
(101.80%↑ Y/Y)
Canceled cashflow
$2,233,154
something is missing
-$1,366,535
Issuance costs from
warrant inducement
$338,667
Issuance costs for sale of
common stock under atm
$75,419
(-49.39%↓ Y/Y)
Equity-based compensation
$672,102
(-41.12%↓ Y/Y)
Accrued liabilities
$333,641
(183.92%↑ Y/Y)
Accounts payable
$47,104
(107.76%↑ Y/Y)
Prepaid expenses
-$17,966
(-105.68%↓ Y/Y)
Deferred offering costs
-$17,933
(-290.45%↓ Y/Y)
Depreciation expense
$504
(-91.48%↓ Y/Y)
Interest receivable
-$161
(99.16%↑ Y/Y)
Net cash used in
operating activities
-$2,233,154
(70.90%↑ Y/Y)
Canceled cashflow
$1,089,411
Net loss
-$3,322,565
(55.77%↑ Y/Y)
Buy us a coffee
Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. (CVKD)